Non-System-Specific Biopharmaceuticals

AstraZeneca PLC

Salesforce

Conference Minutes

INFA

VEEV

TWTR

08391

4502

Below is Dolphin Research's Trans of $Salesforce(CRM.US) FY26 Q4 earnings call.For our earnings analysis, cf. 'Salesforce: The AI replacement thesis sweeps the field — has the SaaS leader been cast aside?'Key takeaways recap1) Q1 guidance: revenue of $11.03–11.08bn, implying reported growth of ~12–13%.Management also guides Q1 CRPO to grow ~14% YoY on a reported basis ...

ServiceNow

Informatica

Veeva Systems -CL

Sunrun

AstraZeneca

Pfizer

Twitter

CORNERSTONE TEC

Takeda Pharmaceutical Co. Ltd.

CRM Trans: Organic rev. growth to re-accelerate in H2 FY

---

AstraZeneca Registers Phase III Clinical Trial for Platinum-Resistant Ovarian Cancer

AstraZeneca Announces Phase III Trial Results for Efzimfotase Alfa

AstraZeneca Receives Approval for Selumetinib Capsules in China

AstraZeneca and Daiichi Sankyo's Enhertu Approved by China's NMPA for New Breast Cancer Treatment

AstraZeneca's Tezolizumab Significantly Reduces Risk of Acute Exacerbations in COPD

Deutsche Bank analyst maintains sell rating on AstraZeneca

AstraZeneca Receives 'Moderate Buy' Consensus Rating from Analysts

AstraZeneca to Build a Cell Therapy Commercial Manufacturing Site and Innovation Center in Shanghai

Berenberg Analyst Maintains Buy Rating on AstraZeneca

AstraZeneca's Imfinzi Approved by the EU for Early Stage Gastric Cancer Perioperative Therapy

FDA to Hold Meeting to Discuss AstraZeneca's Two Oncology Drug Marketing Applications

AstraZeneca Completes Key Safety Study for Liver Cancer Drug Imfinzi/Imjudo

AstraZeneca's ENHERTU® Receives Priority Review in the US

Jefferies Raises Astrazeneca's Target Price

AstraZeneca Finance Subsidiary Issued $2 Billion Fixed-Rate Notes

AstraZeneca Prices $2 Billion Bond Offering

Bernstein Raises Astrazeneca Target Price to 20,500 Pence

AstraZeneca Reports Positive Results from Breztri Aerosphere Phase III Clinical Trials

AstraZeneca May Shift to a More Restricted Rebate Model

AstraZeneca Anticipates Mid-to-High-Single-Digit Growth in Full-Year Revenue

AstraZeneca PLC(AZN.UK)

AstraZeneca PLC Stock Performance Chart